Kornimate/medical-research-clean huggingface dataset:
the effectiveness of endometrial injury in ivf

Conditions: Infertility

Summary: many studies have demonstrated that endometrial scratch significantly increase pregnancy rate in patients undergoing in vitro fertilization and embryo transfer. however, only a limited number of studies have been conducted in frozen thawed transfer (fet) cycle. nowadays, in fet cycles, endometrial scratch is mainly performed on two different time points: 1) luteal phase in the previous cycle; 2)early follicular phase in the current cycle. however, few studies have compared the effectiveness of those two different endometrial scratch methods performed in different timing. the aim of this study is to find the best timing of endometrial scratch in fet cycles.


Eligibility criteria:
inclusion criteria: * to be aged younger than 40 years old; * at least one period ivf-et (fresh or thaw) has been done and not pregnant after at least one qualified blastocyst (more than 3bb) or two qualified embryos (more than ii/6) have been transferred; * there are qualified embryos thawed and the thaw-et period will be taken. exclusion criteria: * malformation of uterus: such as uterus uni-corns, uterus bi-corns, untreated uterus septus, etc.; * history of endometrial diseases: such as intrauterine adhesion, uterine cavity tuberculosis, severe dysplasia of endometrium, etc.; * multiple myomata or endometrioma which causes uterus oppression; * multiple and recurrent endometrial polyps; * pelvic tuberculosis, endometriosis.

Keywords: endometrial scratch ivf randomized controlled study prospective controlled trial different time to perform endometrial scratch in vitro fertilization embryo transfer
computer intervention for prevention of weight regain

Conditions: Obesity

Summary: many overweight patients are able to lose weight successfully, but then regain their weight. the purpose of this study is to develop and test the efficacy of 2 interventions to prevent weight regain in individuals who have recently lost weight. the two interventions being tested are a face-to-face group maintenance program and an internet intervention. these interventions will be compared to a no-contact control group that receives quarterly newsletters. the primary outcome measure is weight regain from baseline to 18-months.


Eligibility criteria:
10% weight loss in past 2 years
magnesium supplementation in type ii diabetes

Conditions: Effect of Magnesium in Diabetes

Summary: this study aims to determine how a 12-week magnesium supplementation with 400 mg magnesium from organic magnesium citrate affects blood glucose control and insulin resistance within patients with type 2 diabetes (hba1c\> 6%) and how the expression of certain mg-sensitive transporting genes is affected .

the examinations are carried out in 50 subjects aged 20-80 years with existing type 2 diabetes (hba1c\> 6%). the target parameters are determined in the blood. blood sampling takes place at confinement, after 6 weeks and at the end of the study (week 12). in addition, blood pressure is determined and general health condition of each subject is recorded by a standardized questionnaire (sf-36).

Eligibility criteria:
inclusion criteria: * type ii diabetics (hba1c \> 6%) exclusion criteria: * pregnancy, lactation * persons with severe renal impairment (glomerular filtration rate \<30 ml / min) * use of insulin, oral antidiabetic drugs, diuretics, antacids or proton pump inhibitors within 4 weeks prior to study start and during the study * intake of vitamin supplements, dietary supplements, mineral products or possibly enriched foods containing magnesium within 4 weeks before study start and during the study

Keywords: magnesium type ii diabetes magnesium-sensitive genes
surface roughness of a dental restorative material and biofilm formation

Conditions: Diabetic; Antibiotic Intake

Summary: in this study we intend to find out the pattern of biofilm accumulation in vivo on various surface finishings. our intention is to prepare polymethylmetacrylate squers on orthodontical brackets,then prepare the surface of the sample and measure the surface roughness with a profilimeter and get the mean value in ra units, then place the brackets on lower premolars and molars for 12 hours, remove them and examine the biofilm formed with confocal scanning microscope.

several studies in the past to assess the effects of surface roughness on the amount of plaque accumulation in vitro, whereas only few performed a modern in vitro assessment of the plaque accumulation. in this study we intend to find out the pattern of biofilm accumulation in vivo on various surface finishings. our intention is to prepare polymethylmetacrylate squers on orthodontical brackets,then prepare the surface of the sample and measure the surface roughness with a profilimeter and get the mean value in ra units, then place the brackets on lower premolars and molars for 12 hours, remove them and examine the biofilm formed with confocal scanning microscope. statistical evaluation of pilot study determined the need to perform this research on twelve(12) candidates. it is our intention to check two materials in each candidate: composite resin and polymethylmetacrylate.

Eligibility criteria:
inclusion criteria: * any patient with intact buccal surfaces of lower molars and premolars exclusion criteria: * patients that used antibiotics in the three months prior to the experiment

Keywords: biofilm formation dental plaque surface roughness dental restoration dental materials
a study of the safety and pharmacokinetics of pro283698 in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this is a phase i multicenter study that will be conducted in the united states and europe.


Eligibility criteria:
inclusion criteria: * ra diagnosed according to the american college of rheumatology (acr) exclusion criteria: * female patients who are pregnant, plan to become pregnant during the study, or are breastfeeding * clinically significant abnormal ecg * history of anaphylactic reactions * positive hepatitis c antibody or hepatitis b surface antigen * positive serology for human immunodeficiency virus (hiv) by quantitative polymerase chain reaction * a history of an autoimmune disease other than ra (other than secondary sjogren syndrome) * significant systemic involvement of ra, including vasculitis, pulmonary fibrosis, or felty syndrome * malignancy, or prior malignancy, other than non-melanoma skin cancer, or cervical carcinoma in situ that has been resected * recent administration of a live, attenuated vaccine, or anticipation that such a live attenuated vaccine will be required during the study or within 60 days after the last dose * concomitant therapy with a biologic agent * recent exposure to any investigational agent * any current or recent signs or symptoms of infection requiring parenteral antibiotic administration * hospitalization for a clinically relevant event within the 4 weeks prior to screening

Keywords: ra
safety of rabeprazole in patients under multiple treatments

Conditions: Gastroesophageal Reflux; Gastric Ulcer

Summary: the purpose of this study is to evaluate the safety of rabeprazole 20mg/day in polymedicated patients and to examine the necessity of adjusted dosage in both therapies (rabeprazole and concomitant drug). proton pump inhibitors (ppi) act in the final step of the gastric secretion. ppi's block atp-ase h+/k+ in gastric parietals cells. it has been described that inhibition of acid secretion has produced the recovery of the gastroesophageal pathology in a high percentage of the patients resistant to conventional drugs. in this context, the objective of the study is to evaluate the safety of rabeprazole as a concomitant treatment and examine the clinical practice the interaction with drugs whose absorption has gastric ph dependence.

rabeprazole is a new proton pump inhibitor (ppi) with potent anti-secretion action and dose-dependence activity. rabeprazole is rapidly eliminated by hepatic metabolism and renal clearance. in previous studies in healthy volunteers, interactions between sodium rabeprazole and drugs such as warfarin, theophyline, diazepam and phenytoin have not been found. the objective of the study is to evaluate the safety of rabeprazole as concomitant treatment and examine the clinical practice of the interaction with drugs whose absorption has a gastric ph dependence. this is an observational, multicenter, open and prospective study. it is expected to enroll 500 patients receiving rabeprazole and a concomitant drug (one or more). all data collected will be prospective and will include the following: demographic data, adherence and compliance with treatment, lifestyle (smoking and alcohol consumption) and dose of rabeprazole. safety analysis will be based on adverse events. observational study: for patients with duodenal or gastric ulcer: rabeprazole 20mg per day, orally, for 4-6 weeks; for patients with erosive or ulcerate gastroesophagic reflux: rabeprazole orally 20mg/ per day, 4-8 weeks; for patients with gastroesophagic reflux requiring prolonged treatment: rabeprazole orally 10 or 20 mg per day; for patients with h. pylori: rabeprazole orally 20mg twice per day , clarithromycin orally 500mg 2 times per day and amoxicillin 1gram orally twice daily for 1 week.

Eligibility criteria:
inclusion criteria: * patients receiving rabeprazole and a concomitant drug (one or more) such a non-steroidal anti-inflammatory drugs (nsaid), benzodiazepines or corticoids exclusion criteria: * pregnant or lactating patients * other severe concomitant pathologies * history or drug or alcohol abuse

Keywords: interactions adjusted doses duodenal ulcer gastric ulcer erosive or ulcerate gastroesophageal reflux rabeprazole gastroesophageal reflux
stability and crestal bone changes around implants placed at crestal versus subcrestal level in controlled type two diabetic patients

Conditions: Dental Implant; Diabetes

Summary: the objective of this study is to assess clinically the peri implant tissues, the radiological marginal bone loss and the stability around implants placed at the crestal versus the subcrestal level in type 2 controlled diabetic patients using cone beam computed tomography


Eligibility criteria:
inclusion criteria * type 2 controlled diabetic patients * patients with at least one missing tooth in lower jaw. * patients with sufficient alveolar ridge height and width (no need for bone augmentation). * patients with sufficient inter-occlusal distance that will allow future restoration. * patients with healthy periodontium. exclusion criteria * smokers. * para functional habits. * bad oral hygiene measured according to o'leary plaque index. * pregnant women. * other local or systemic diseases that may compromise the surgical procedure, healing or osteointegration.
evaluation of peripheral nerve stimulation for acute treatment of migraine pain

Conditions: Episodic Migraine

Summary: clinical study to determine the responder rate of the theranova migraine treatment system to that of a sham control treatment.


Eligibility criteria:
inclusion criteria: * 18-100 years, inclusive * diagnosis of episodic migraine with and without aura per international headache society diagnostic criteria * 4-14 migraine days per month * ability to provide informed consent * demonstrates no contraindication to the use of electrical nerve stimulation * capable and willing to follow all study-related procedures exclusion criteria: * currently pregnant or breastfeeding, pregnant within the past 6 months or intends to become pregnant during the enrollment period * diagnosis of chronic migraine or other forms of primary or secondary headache disorders, including medication overuse headache per international headache society diagnostic criteria * any medical condition that would, in the opinion of the investigator, make the subject ineligible * has received botulinum toxin injections within the past 3 months * is currently implanted with an electrical and/or neurostimulator devic, including but not limited to cardiac pacemaker or defibrillator, vagal neurostimulator, sacral stimulator, bone growth stimulator, or cochlear implant * use of investigational drug/device therapy within the past 4 weeks * deemed unsuitable for enrollment in study by the investigator based on subjects' history or physical examination (including bleeding disorders, anticoagulant medications and peripheral neuropathy) * no changes in preventive medications (or other medications determined to potentially interfere with the study) in the previous 30 days and no intent to change it during the study
increase of handgrip strength after the use of removable partial dentures.

Conditions: Sarcopenia

Summary: a common goal of the health professions is to keep the elderly functional, preventing sarcopenia and frailty. is there an association between handgrip strength in partially edentulous elderlies after completing their dentition with removable partial dentures?

a common goal of the health professions is to keep the elderly functional, preventing sarcopenia and frailty. is there an association between handgrip strength in partially edentulous elderlies after completing their dentition with removable partial dentures?

Eligibility criteria:
inclusion criteria: * agree to participate by signing the voluntary informed consent form * qualify according to the eichner index in any of the categories that represent the loss of premolars and molars: b3-b4-c1-and c2. exclusion criteria: * not accepting to participate * cognitive or auditory sensory impairment- * being dependent in activities of daily living * belonging to another category of the eichner index

Keywords: removable partial dentures
topical tranexamic acid plus perivascular vasopressin at the time of abdominal myomectomy

Conditions: Myoma

Summary: in this study, the investigators will investigate the effectiveness of a topical tranexamic acid plus perivascular vasopressin compared with perivascular vasopressin alone for the reduction of blood loss at the time of myomectomy

uterine fibroids are the most common female pelvic tumors occurring in about 15% to 30% of women in the reproductive age group. the major problem with myomectomy is excessive bleeding from the increased uterine blood supply. this can be life-threatening, resulting in blood transfusions, febrile morbidity, and potentially in loss of reproductive potential from a hysterectomy. knowledge of the effectiveness of the interventions used to reduce blood loss during myomectomy is essential to enable evidence-based clinical decisions. topical application of tranexamic acid(ta) provides a high drug concentration at the site of the wound and a low systemic concentration. studies from cardiac and orthopedic surgery have shown an equal or superior effect of topical compared with intravenous ta on both bleeding and transfusion requirement. topical treatment is cost-effective, and adverse effects or drug interactions have not been reported

Eligibility criteria:
inclusion criteria: * patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging * age ≥ 18 years and ≤ 50 years * pre-operative hemoglobin \>8 g/dl * ability to understand and the willingness to sign a written informed consent. * admissible medical/surgical history * five or less symptomatic uterine myomas * all myomas are subserous or intramural. * uterine size less than 24 weeks of pregnancy exclusion criteria: * patients who have had a prior abdominal myomectomy * post-menopausal women * patients with known bleeding/clotting disorders * patients with a history of gynecologic malignancy * hypertension. * cardiac and pulmonary diseases. * obesity (body mass index \> 30 kg/m2). * history of allergic reactions attributed to misoprostol * cases that will require intraoperative conversion of myomectomy to hysterectomy.

Keywords: abdominal myomectomy tranexamic acid vasopressin
the use of brief motivational interviewing in community health centers.

Conditions: Healthy Subjects

Summary: the research project aims to detect the effect of the brief motivational interview (bmi) on the motivation to change risky behaviors and the adoption of healthy lifestyles by citizens attending community health centers (cdc). the controlled, multicenter, prospective design study involves the enrollment of 304 people, with 152 at the borgo reno cdc and 152 at the navile cdc.

the study will include 152 citizens who use the services of the borgo reno community health center and 152 citizens from the navile community health center. eligible participants will be identified with the help of specialist medical staff and nursing staff at the facility. once an eligible participant is identified, the brief motivational interview (bmi) can be conducted during regular institutional activities (if the operator on duty at that time is trained to conduct the bmi and after obtaining informed consent and completing the sf-36 questionnaire) or by scheduling an appointment with the nursing and/or facility staff for a dedicated bmi clinic. students from the degree courses in "psychology," "human nutrition, wellness, and health," and "wellness, sport, and health," who are appropriately trained and authorized, will contribute to the research study by providing all necessary information. participants in the experimental group who are given an appointment will sign the informed consent for participation and consent for the processing of personal and sensitive data. they will also receive a letter for their general practitioner explaining the study procedures. inclusion and exclusion criteria will be assessed. if the criteria are met, the citizen will be included in the study. citizens enrolled at the borgo reno community health center will be assigned to the experimental group (with intervention), while those enrolled at the navile community health center will be part of the control group (without intervention). a clinic will be dedicated to this study, where professionals (specialist/home nursing staff, dietitians, physiotherapists, ifec) from the community health center who have received training from the ccm course on brief motivational interviewing will conduct the sessions.

Eligibility criteria:
inclusion criteria: * first visit to the cardiology or endocrinology/diabetology or rheumatology or basic dietetics services or other medical specialties of the borgo-reno or navile community home or referred to them. * resident in the ausl of bologna * age ≥18 years exclusion criteria: * second or more visits to the cardiology or endocrinology/diabetology or rheumatology or basic dietetics services, or other medical specialties of the borgo-reno or navile community house or referred to them. * first visit to a service not indicated in the inclusion criteria * not resident in the territory of the ausl of bologna * age \<18 years

Keywords: motivational interviewing
trial of tian jiu therapy for allergic rhinitis

Conditions: Allergic Rhinitis (AR)

Summary: the aim of this study is to investigate the efficacy and safety of tian jiu in the treatment of allergic rhinitis compared with placebo and waitlist patients in hong kong.

this will be a prospective, randomized, single-blinded, controlled trial in patients with ar. after a one-week run-in period, eligible subjects will be randomly assigned to the tian jiu group, placebo-control group and waitlist-control group. the tj and placebo-control groups will undergo a 4-week treatment with one session per week and one 4-week post-treatment follow-up. participants in the waitlist-control group will not receive any treatment during the first 4 weeks but will be required to be assessed. the total study period will be nine weeks.

Eligibility criteria:
inclusion criteria: * positive skin prick tests * high circulating levels of allergen-specific ige antibody detected by a specific blood test for allergy called radioallergosorbent test (rast)\] * clinical history or allergen to have been identified * nasal provocation (test) exclusion criteria: * allergic asthma, moderate to severe atopic dermatitis, autoimmune disorders, severe chronic inflammatory diseases, history of anaphylactic reactions, hypersensitivity to cetirizine or related drugs, specific immunotherapy during the past 3 years or planned in the next 2 years, pregnancy or breastfeeding.
study of radiation (rt) concurrent with cetuximab in patients with advanced head and neck squamous cell carcinoma (scc)

Conditions: Head and Neck Cancer

Summary: this is a single-arm, phase ii trial to characterize the clinical outcome of standard of care, cetuximab concurrent with radiation, in a special population (head and neck cancer patients who cannot tolerate concurrent chemoradiotherapy due to advanced age, poor performance status or concurrent illness), and to determine if biomarker response to a loading dose of cetuximab is predictive of that outcome.

primary objective 1: determine changes in tumor egfr, pegfr, downstream signaling and novel phosphoproteins following a loading dose of cetuximab in patients who are poor candidates for chemoradiation (age =70 years or with significant co-morbidities) and are therefore treated with cetuximab with radiation. primary objective 2: characterize clinical outcomes, including local recurrence, progression-free survival and overall survival in these patients, and correlate these clinical outcomes with the changes in tumor egfr, pegfr, downstream signaling, and novel phosphoproteins. primary objective 3: describe the toxicity, in particular mucositis/dysphagia, of this regimen. secondary objective 1: conduct normal mucosa egfr assessment for comparison with tumor sample. secondary objective 2: correlate hpv presence and titer with p53 status and clinical outcome.

Eligibility criteria:
inclusion criteria: * patients must have pathologically-confirmed, previously untreated, clinically accessible (without general anesthesia) locally advanced squamous cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, or nonresectable head and neck squamous cell carcinomas of the skin. * patients will be limited to: * ≥ 70 years of age, or * with co-morbidities that preclude treatment with standard platinum-based chemotherapy, as determined by the treating physician, or * kps ≤ 80, or * creatinine clearance \< 30 cc/min * laboratory criteria: * wbc \> 3500/ul * granulocyte \> 1500/ul * platelet count \> 100,000/ul * total bilirubin \< 1.5 x uln * ast and alt \< 2.5 x uln * patients must give documented informed consent to participate in this study. exclusion criteria: * prior head and neck malignancy, or history of other prior non-head and neck malignancy within the past 3 years (excluding skin cancer and early stage treated prostate cancer). * prior head and neck radiation or chemotherapy. * documented evidence of distant metastases. * patients with nasopharyngeal carcinoma. * any medical or psychiatric illness, which, in the opinion of the principal investigator, would compromise the patient's ability to tolerate this treatment. * patients with psychiatric/social situations that would limit compliance with study requirements are not eligible. * patients with prior anti-epidermal growth-factor receptor antibody therapy (antibody or small molecule). * patients residing in prison.

Keywords: scc head and neck cancer